Compare Quest Diagnostics Inc (DGX) vs Electronic Arts Inc. (EA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Electronic Arts Inc. — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Electronic Arts Inc. trades at $206.65 (market cap $51.82B). The key difference: Electronic Arts Inc. is far larger — about 2.3× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | EA | |
|---|---|---|
Market Cap | $22.80B | $51.82B |
Sector | Health | Technology |
52-Week High | $216.02 | $206.65 |
52-Week Low | $166.42 | $147.79 |
Enterprise Value | $28.82B | $50.39B |
Dividend Yield | 1.67% | 0.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Electronic Arts (EA) trades at $206.35, down 0.03% on the day, with a bullish technical signal from moving averages and mixed earnings performance including a recent Q4 2025 beat. The company maintains strong profitability with a 78.97% gross margin and 11.78% net margin, though valuation ratios like P/E of 58.79 appear elevated. Recent launches of EA SPORTS College Football 27 and UFC 6, plus the new EA Advertising platform, highlight ongoing growth initiatives.
Outlook is cautiously optimistic given analyst consensus leaning Hold (56.06%) versus Buy (43.94%), with risks including earnings volatility and high valuation. The potential $55 billion acquisition by Saudi investors, pending EU approval, could significantly impact shareholder value, while consistent cash flow from operations supports dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Electronic Arts Inc.
EA is one of the world's largest third-party video game publishers and has transitioned from a console-based video game publisher to the one of the largest publishers on consoles, PC, and mobile. The firm owns number of large franchises, including Madden, FIFA, Battlefield, Apex Legends, Mass Effect, Dragon's Age, and Need for Speed.
Read more on EA →
